Description_x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days._x000D_ Caution_x000D_ category 1 skin sensitizer